Endologix announces top-line results of Nellix endovascular aneurysm sealing system study

Tim Casey | | Cardiovascular Business | Vascular & Endovascular

Endologix, Inc. announced on May 26 that its Nellix endovascular aneurysm sealing system had met the primary safety and efficacy endpoints in the EVAS FORWARD-IDE study.

The Nellix system is intended for the endovascular repair of infrarenal abdominal aortic aneurysms. The system received a CE Mark in April.

Endologix submitted results of the prospective, single-arm EVAS FORWARD-IDE study to the FDA as part of its premarket approval submission. The company said the FDA plans on making an approval decision on the Nellix system by the end of 2016 or early 2017.

The study enrolled 150 patients at 30 centers in the U.S. and Europe between January and November 2014. Endologix said there was a 100 percent procedural technical success rate.

Further, 2.7 percent of patients had a major adverse event at 30 days, which met the primary safety endpoint, while the one-year treatment success rate of 94 percent met the primary effectiveness endpoint.

In addition, there was a 96 percent freedom from all-cause mortality, a 99 percent freedom from abdominal aortic aneurysm-related mortality and a 96.6 percent freedom from device-related secondary interventions. Meanwhile, 3.1 percent of patients had endoleaks at one year.

Lead researcher Jeffrey P. Carpenter, MD, of the Cooper Health System in New Jersey, will present full results of the study on June 11 at the Society for Vascular Surgery annual meeting.

In October 2015, Endologix and TriVascular Technologies signed a definitive merger agreement in a stock and cash deal valued at approximately $211 million. For the first quarter of 2016, Endologix's revenue increased 16 percent to $42.4 million, while it posted a net loss of $47.7 million.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."